Pharmaceuticals

Gastric Antisecretory Drug Market Growth Projection: Expected to Surpass $20.7 Billion by 2030 at 5.8% CAGR

February 16, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the gastric antisecretory drug market from 2026–2035 with trusted insights from The Business Research Company

By how much is the Gastric Antisecretory Drug Market expected to grow between 2026 and 2030?

The gastric antisecretory drug market size has seen substantial growth over recent years. It is anticipated to increase from $15.63 billion in 2025 to $16.53 billion in 2026, registering a compound annual growth rate (CAGR) of 5.7%. This historical expansion can be linked to the high occurrence of acid-related disorders, an increase in gastroesophageal reflux disease diagnoses, the broadening of hospital pharmacies, the widespread use of h2 receptor antagonists, and a rise in self-medication trends.

The gastric antisecretory drug market size is projected to experience robust expansion in the coming years, with its valuation expected to reach $20.7 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.8%. This anticipated growth is primarily driven by an expanding aging population, an increase in stress-related gastric disorders, the enlargement of over-the-counter (OTC) drug markets, heightened healthcare awareness, and the development of safer long-term therapies. Key trends influencing the market during the forecast period include the increasing use of proton pump inhibitors, a rising demand for sustained acid suppression, a growing preference for oral drug formulations, broader over-the-counter availability, and an amplified focus on comprehensive gastrointestinal disease management.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24222&type=smp

Which Drivers Are Influencing Market Acceleration In The Gastric Antisecretory Drug Market?

The increasing occurrence of gastrointestinal conditions is expected to drive expansion within the gastric antisecretory drug market over the upcoming period. These disorders impact the digestive system, encompassing the stomach, intestines, and related organs, resulting in indications like discomfort, distension, and changes in bowel habits. The surge in gastrointestinal ailments largely stems from inadequate eating patterns, where consuming too many processed foods and too little fiber contributes to disruptions in gut flora and compromised digestion. Gastric antisecretory medications are necessary because an overabundance of stomach acid can harm the digestive tract’s defensive layer, causing irritation or lesions, which these drugs mitigate by lowering acid secretion. As an illustration, inJune 2025, the Turkish Journal Of Gastroenterology, a Turkey-based journal, reported that 6.9 million people worldwide are presently afflicted with inflammatory bowel disease (IBD). Consequently, the growing incidence of gastrointestinal conditions will stimulate the expansion of the gastric antisecretory drug market.

What Segments Are Identified Within The Structure Of The Gastric Antisecretory Drug Market?

The gastric antisecretory drug market covered in this report is segmented –

1) By Drug Class: Proton Pump Inhibitors (PPIs), H2 Receptor Antagonists, Antacids, Prostaglandin Analogs

2) By Route Of Administration: Oral, Intravenous

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

4) By Application: Gastroesophageal Reflux Disease, Peptic Ulcer Disease, Zollinger-Ellison Syndrome, Other Applications

Subsegments:

1) By Proton Pump Inhibitors (PPIs): Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, Rabeprazole, Dexlansoprazole

2) By H2 Receptor Antagonists: Ranitidine, Famotidine, Cimetidine, Nizatidine

3) By Antacids: Magnesium Hydroxide, Calcium Carbonate, Aluminum Hydroxide, Sodium Bicarbonate, Combination Antacids

4) By Prostaglandin Analogs: Misoprostol, Enprostil

Which Competitive Trends Are Impacting The Structure Of The Gastric Antisecretory Drug Market?

Leading companies in the gastric antisecretory drug market are concentrating on developing sophisticated products, such as antisecretory compounds, to deliver more enduring relief. Antisecretory compounds are agents that decrease or prevent the discharge of bodily fluids, notably gastric acid, by influencing specific cellular routes or receptors. For example, in June 2024, Akums Drugs and Pharmaceuticals, an India-based pharmaceutical company, introduced Rabeprazole + Levosulpiride SR Capsules, a novel preparation for Gastrointestinal patients. This preparation distinctively merges rabeprazole sodium, a potent antisecretory agent that selectively obstructs the H?/K? ATPase in gastric parietal cells, with levosulpiride, recognized for its central antidopaminergic and antiemetic attributes. The capsule supplies 40 mg of enteric-coated rabeprazole and 75 mg of sustained-release levosulpiride, guaranteeing precise and prolonged therapeutic effects. Its combined action tackles both acid reduction and the modulation of gastrointestinal movement.

Which Major Industry Participants Are Leading The Gastric Antisecretory Drug Market Growth?

Major companies operating in the gastric antisecretory drug market are Pfizer Inc., Bayer AG, AstraZeneca plc, Takeda Pharmaceutical Company Ltd., Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, Chemo Biological, Spansules Pharmatech Pvt. Ltd., Phoenix Biologicals Pvt. Ltd., Centurion Remedies Private Limited, Solitaire Pharmacia Pvt. Ltd., Shreeji Pharma International, Estrellas Life Sciences Private Limited, 3s Corporation, Actiza Pharmaceutical Private Limited, Lark Laboratories, Cytonova Labs International Private Limited, Luckys Pharma Lab Pvt. Ltd., Lexicare Pharma Pvt. Ltd., Mustcure Healthcare LLP

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/gastric-antisecretory-drug-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Gastric Antisecretory Drug Market?

North America was the largest region in the gastric antisecretory drug market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastric antisecretory drug market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Gastric Antisecretory Drug Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24222&type=smp

Browse Through More Reports Similar to the Global Gastric Antisecretory Drug Market 2026, By The Business Research Company

Gastrointestinal Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/gastrointestinal-drugs-global-market

Gastric Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report

Gastroparesis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795